FibroBiologics, Inc., a clinical-stage biotechnology company, has announced positive updates from its psoriasis research program. The company reported favorable IND-enabling results demonstrating the potential of human dermal fibroblast (HDF) spheroids as a therapeutic approach for chronic-relapse psoriasis. Currently, FibroBiologics is expanding its research efforts by exploring repeated dosing regimens and conducting systemic and local cytokine profiling, along with histopathological assessments of skin lesions. These studies aim to deepen the understanding of the underlying mechanisms and strengthen the clinical foundation for further advancement. The results from these studies have been presented and mark a pivotal milestone in the company's path toward developing treatments for chronic inflammatory diseases.